Identidad arquitectónica y la reivindicación de la materialidad en la casa hacienda Fortín, sector 7 del distrito de Carabayllo – 2022

En el distrito de Carabayllo se ha observado la ausencia de identidad arquitectónica en la Casa Hacienda Fortín, esta ha ido cambiando con el transcurrir del tiempo, generado así deterioro del patrimonio histórico y cultural, que enriquece a la zona, por parte de los mismos pobladores y la incapacidad de la gestión del estado. Nuestro estudio tiene como finalidad, Determinar qué relación existe entre Identidad arquitectónica y la Reivindicación de la Materialidad en la “Casa Hacienda Fortín”, Sector 7 del Distrito de Carabayllo – 2022. La metodología es tipo básica, con un enfoque cuantitativo y un diseño no experimental, alcance correlacional, nuestro objetivo es recopilar los datos en un tiempo determinado, nuestra muestra está compuesta por 169 pobladores del mismo sector, esto nos sirve para la recepción de los datos, se empleó el cuestionario como instrumento, obtuvimos como resultado que existe una relación positiva alta entre la identidad arquitectónica y la materialidad en la Casa Hacienda Fortín, debido a la alta aprobación que tienen los habitantes. En conclusión, el patrimonio cultural tiene una relación profunda con la identidad arquitectónica ya que pese a los años no pierde su autenticidad a través de su materialidad

Efecto del empleo de composts contaminados con metales pesados en la producción de hortalizas.

El movimiento de la Agricultura Urbana, ha possibilitado la producción de alimentos con bajos insumos de forma exitosa en las ciudades. Dentro del mismo, sobresalen los organopónicos, dirigidos fundamentalmente a la producción de hortalizas de hojas y especies condimentosas en sustratos orgánicos, lo que ha incrementado la demanda de fuentes orgánicas con este fin

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Etude expérimentale du comportement hygromécanique du Douglas à l'échelle du cerne

National audienceLorsque l'Humidité Relative (HR) varie, le bois se déforme de manière anisotrope à l'échelle macroscopique. Afin d'optimiser l'utilisation du bois dans ses applications et d'améliorer les modèles de prédiction de son comportement hygromécanique, il est nécessaire d'identifier les éléments microstructuraux à chaque échelle qui ont une influence notable

Validity of four commercially available metabolic carts for assessing resting metabolic rate and respiratory exchange ratio in non-ventilated humans.

The validity of most commercially available metabolic cart is mostly unknown. Thus, we aimed to determine the accuracy, precision, within-subject reproducibility, and concordance of RMR and RER measured by four commercially available metabolic carts [Cosmed Q-NRG, Vyaire Vyntus CPX, Maastricht Instruments Omnical, and Medgraphics Ultima CardiO2]. Further, we studied whether a previously proposed simulation-based post-calorimetric calibration of cart readouts [individual calibration control evaluation (ICcE)] modify the RMR and RER reproducibility and concordance. Three experiments simulating different RMR and RER by controlled pure gas (N2 and CO2) infusions were conducted on 5 non-consecutive days. Moreover, 30-min methanol burns were performed on 3 non-consecutive days. Lastly, the RMR and RER of 29 young non-ventilated adults (11 women; 25 ± 4 years-old; BMI: 24.1 ± 3.2 kg/m2) were assessed twice using each instrument, 24 hours apart, under standardized conditions. The Omnical presented the lowest measurement error for RER (Omnical = 1.7 ± 0.9%; Vyntus = 4.5 ± 2.0%; Q-NRG = 6.6 ± 1.9%; Ultima = 6.8 ± 6.5%) and EE (Omnical = 1.5 ± 0.5%; Q-NRG = 2.5 ± 1.3%; Ultima = 10.7 ± 11.0%; Vyntus = 13.8 ± 5.0%) in all in vitro experiments (controlled pure gas infusions and methanol burns). In humans, the 4 metabolic carts provided discordant RMR and RER estimations (all P  The 4 metabolic carts provided discordant measurements of RMR and RER. Overall, the Omnical provides more accurate and precise estimations of RMR and RER than the Q-NRG, Vyntus and Ultima CardiO2, and might be considered the best for assessing RMR and RER in non-ventilated humans. Finally, our results do not support the use of an ICcE procedure